Oncolytics Biotech(ONCY)
$0.35-0.04 (-10.26%)
ONCY
Oncolytics Biotech financials statements
$0.35
At close:-0.04 (-10.26%)
Want to see ONCY full AI Analyst Report?
Oncolytics Biotech (ONCY) Ratios
1,682 Followers
Oncolytics Biotech Ratios
ONCY's free cash flow for Q3 2026 was C$-6.98M. For the 2026 fiscal year, ONCY's free cash flow was increased by C$5.97K and operating cash flow was C$-6.99M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.12 | 2.82 | 9.01 | 9.05 | 16.69 |
| Quick Ratio | 1.12 | 2.82 | 9.01 | 9.05 | 16.69 |
| Cash Ratio | 0.85 | 2.38 | 8.24 | 2.96 | 15.34 |
| Solvency Ratio | -1.84 | -2.23 | -1.80 | -1.73 | -2.11 |
| Operating Cash Flow Ratio | -2.40 | -4.03 | -6.71 | -5.92 | -8.34 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | C$ -6.23M | C$ 4.67M | C$ 26.92M | C$ 24.85M | C$ 35.12M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.07 | 0.05 | 0.01 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | -0.15 | 0.18 | 0.02 | 0.01 | 0.02 |
| Debt-to-Capital Ratio | -0.17 | 0.15 | 0.02 | 0.01 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -2.00 | 3.37 | 1.41 | 1.41 | 1.27 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Net Debt to EBITDA | 0.22 | 0.43 | 1.71 | 0.60 | 1.97 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.28% | 100.41% | 100.35% | 100.34% | 100.19% |
| EBT Per EBIT | 99.84% | 90.27% | 81.84% | 91.93% | 100.08% |
| Return on Assets (ROA) | -276.44% | -157.08% | -52.97% | -51.10% | -45.73% |
| Return on Equity (ROE) | 551.71% | -530.00% | -74.60% | -71.98% | -58.12% |
| Return on Capital Employed (ROCE) | -1413.55% | -259.13% | -72.39% | -61.94% | -48.45% |
| Return on Invested Capital (ROIC) | -1250.57% | -253.92% | -72.12% | -61.54% | -48.12% |
| Return on Tangible Assets | -276.44% | -157.08% | -52.97% | -51.10% | -45.73% |
| Earnings Yield | -25.02% | -31.55% | -17.40% | -14.89% | -22.31% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.08 | 0.28 | 0.13 | 0.61 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -4560.40 | -1322.66 | -2729.84 | -601.29 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 4560.40 | 1322.66 | 2729.84 | 601.29 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.21 | -0.35 | -0.42 | -0.40 | -0.42 |
| Free Cash Flow Per Share | -0.21 | -0.36 | -0.42 | -0.40 | -0.42 |
| Dividend Paid and CapEx Coverage Ratio | -3352.00 | -112.83 | -3556.00 | -424.64 | -78.45 |
| Capital Expenditure Coverage Ratio | -3352.00 | -112.83 | -3556.00 | -424.64 | -78.45 |
| Operating Cash Flow Coverage Ratio | -26.03 | -25.34 | -67.25 | -62.61 | -34.25 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -17.50% | -27.07% | -24.08% | -18.28% | -24.16% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.92 | -3.21 | -5.75 | -6.71 | -4.48 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -22.05 | 16.80 | 4.29 | 4.83 | 2.60 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.71 | -3.69 | -4.15 | -5.47 | -4.14 |
| Price-to-Operating Cash Flow Ratio | -5.72 | -3.73 | -4.15 | -5.48 | -4.19 |
| Price-to-Earnings Growth (PEG) Ratio | -0.08 | 0.00 | 1.24 | 0.55 | -2.15 |
| Enterprise Value Multiple | -3.79 | -2.45 | -4.14 | -6.24 | -2.60 |
| Enterprise Value | 108.59M | 85.63M | 83.69M | 116.79M | 53.42M |
| EV to EBITDA | -3.79 | -2.45 | -4.14 | -6.24 | -2.60 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -5.40 | -3.15 | -2.94 | -4.99 | -2.35 |
| EV to Operating Cash Flow | -5.40 | -3.18 | -2.94 | -5.00 | -2.38 |
| Tangible Book Value Per Share | -0.05 | 0.08 | 0.41 | 0.46 | 0.67 |
| Shareholders’ Equity Per Share | -0.05 | 0.08 | 0.41 | 0.46 | 0.67 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.30 | -0.41 | -0.30 | -0.33 | -0.39 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 0.90 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.70 | 0.85 | 1.03 | 0.94 | 0.85 |
Currency in CAD

